Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic or cytologic diagnosis non-small cell lung cancer (NSCLC) (Stage IIIB or IV)~* Have not received any prior chemotherapy, molecular therapy, immunotherapy, biological therapy, or radiotherapy. Exception: palliative radiotherapy that is completed at least 4 weeks prior to study enrolment.~* Have 'never smoked' (defined as having smoked \<100 cigarettes during his/her lifetime)~* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1~Exclusion Criteria:~* Concurrent administration of any other tumor therapy~* Other co-existing malignancies~* Pregnancy or breast feeding~* Serious concomitant disorders~* Inability or unwillingness to take folic acid or vitamin B12 supplementation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed/Cisplatin/Gefitinib (Type: EXPERIMENTAL): Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by gefitinib 250 mg administered orally, once daily, until disease progression or unacceptable toxicity.
- Pemetrexed/Cisplatin (Type: EXPERIMENTAL): Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by pemetrexed 500 mg/m2 administered by IV infusion (with optional cisplatin 75 mg/m2 for up to 2 additional cycles) until disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).